These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 10878494)

  • 1. Binding of glucocorticoids to human nasal tissue in vitro.
    Esmailpour N; Högger P; Rohdewald P
    Int Arch Allergy Immunol; 2000 Jun; 122(2):151-4. PubMed ID: 10878494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of intranasal corticosteroids.
    Szefler SJ
    J Allergy Clin Immunol; 2001 Jul; 108(1 Suppl):S26-31. PubMed ID: 11449203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasal retention of budesonide and fluticasone in man: formation of airway mucosal budesonide-esters in vivo.
    Petersen H; Kullberg A; Edsbäcker S; Greiff L
    Br J Clin Pharmacol; 2001 Feb; 51(2):159-63. PubMed ID: 11259988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor.
    Högger P; Rohdewald P
    Steroids; 1994 Oct; 59(10):597-602. PubMed ID: 7878687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes.
    Moore CD; Roberts JK; Orton CR; Murai T; Fidler TP; Reilly CA; Ward RM; Yost GS
    Drug Metab Dispos; 2013 Feb; 41(2):379-89. PubMed ID: 23143891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro metabolism of beclomethasone dipropionate, budesonide, ciclesonide, and fluticasone propionate in human lung precision-cut tissue slices.
    Nave R; Fisher R; McCracken N
    Respir Res; 2007 Sep; 8(1):65. PubMed ID: 17883839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluticasone propionate aqueous nasal spray in the treatment of nasal polyposis.
    Holmberg K; Juliusson S; Balder B; Smith DL; Richards DH; Karlsson G
    Ann Allergy Asthma Immunol; 1997 Mar; 78(3):270-6. PubMed ID: 9087151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nasal cytology in patients with allergic rhinitis: effects of intranasal fluticasone propionate.
    Meltzer EO; Orgel HA; Rogenes PR; Field EA
    J Allergy Clin Immunol; 1994 Oct; 94(4):708-15. PubMed ID: 7930304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of glucocorticoid receptor mRNA in nasal mucosa by local administration of fluticasone and budesonide.
    Knutsson PU; Brönnegård M; Marcus C; Stierna P
    J Allergy Clin Immunol; 1996 Feb; 97(2):655-61. PubMed ID: 8621851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a novel model for comparative evaluation of intranasal pharmacokinetics and effects of anti-allergic nasal sprays.
    Baumann D; Bachert C; Högger P
    Eur J Pharm Biopharm; 2012 Jan; 80(1):156-63. PubMed ID: 21945271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis.
    Yáñez A; Rodrigo GJ
    Ann Allergy Asthma Immunol; 2002 Nov; 89(5):479-84. PubMed ID: 12452206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone diproprionate.
    van As A; Bronsky EA; Dockhorn RJ; Grossman J; Lumry W; Meltzer EO; Seltzer JM; Rogenes PR
    J Allergy Clin Immunol; 1993 Jun; 91(6):1146-54. PubMed ID: 8509578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of high-dose inhaled corticosteroids on plasma cortisol concentrations in healthy adults.
    Brus R
    Arch Intern Med; 1999 Sep; 159(16):1903-8. PubMed ID: 10493320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids.
    Smith CL; Kreutner W
    Arzneimittelforschung; 1998 Sep; 48(9):956-60. PubMed ID: 9793625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissolution in nasal fluid, retention and anti-inflammatory activity of fluticasone furoate in human nasal tissue ex vivo.
    Baumann D; Bachert C; Högger P
    Clin Exp Allergy; 2009 Oct; 39(10):1540-50. PubMed ID: 19538495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in allergic rhinitis.
    Bryson HM; Faulds D
    Drugs; 1992 May; 43(5):760-75. PubMed ID: 1379151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved asthma control after changing from low-to-medium doses of other inhaled corticosteroids to low-dose fluticasone propionate.
    Stoloff SW; Srebro SH; Edwards LD; Johnson MC; Rickard KA
    MedGenMed; 2001 Jun; 3(3):2. PubMed ID: 11549975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic bioavailability and potency of high-dose inhaled corticosteroids: a comparison of four inhaler devices and three drugs in healthy adult volunteers.
    Wales D; Makker H; Kane J; McDowell P; O'Driscoll BR
    Chest; 1999 May; 115(5):1278-84. PubMed ID: 10334140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of interleukin-5 mediated eosinophil viability by fluticasone 17-propionate: comparison with other glucocorticoids.
    Hagan JB; Kita H; Gleich GJ
    Clin Exp Allergy; 1998 Aug; 28(8):999-1006. PubMed ID: 9756205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network.
    Kamada AK; Szefler SJ; Martin RJ; Boushey HA; Chinchilli VM; Drazen JM; Fish JE; Israel E; Lazarus SC; Lemanske RF
    Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1739-48. PubMed ID: 8665030
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.